Commercialize autoantibody test for early detection and monitoring of autoimmune diseases
Augurex Life Sciences Corp.
6 enregistrements totalisant 5,602,399.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Par ministère
| Développement économique Canada pour le Pacifique | $5,473,500 | 2 enregistrements |
| Conseil national de recherches Canada | $128,899 | 4 enregistrements |
Enregistrements
Support sales and marketing of autoimmune disease test for the point-of-care market
The main objective of this project is to identify a lead biological candidate for the treatment of Rheumatoid Arthritis (RA).
The purpose of this CanExport SMEs agreement is to support small- and medium-sized enterprises (SMEs) for activities related to export market development that are part of an export business case for a...
The 14-3-3 eta JOINTstat® test can be used as an aid in the diagnosis of patients with Rheumatoid Arthritis. Augurex plans to commercialize 14-3-3 eta tests and reagents in Germany & Australia to expa...
The 14-3-3η JOINTstat test may be used as an aid in the diagnosis of patients with Rheumatoid Arthritis. Augurex plans to commercialize 14-3-3η tests and reagents in Germany to expand our commercial...